Indian firm takes over German biologics plant
An Indian firm has taken over the contract biologics manufacturing business of German corporation Siegfried.
An Indian firm has taken over the contract biologics manufacturing business of German corporation Siegfried.
Two new techniques have been developed that could signal the end of PCR (polymerase chain reaction) amplification for sequencing applications and dramatically increase the efficiency of sample preparation.
Biogen Idec has announced it is seeking a buyer for the company and has already received several expressions of interest - including a reputed $23bn (€16.2bn) bid from billionaire corporate raider Carl Icahn.
Moody's Investors Service believes that things are set to get worse for the US pharma industry and has revised is credit ratings outlook from stable to negative.